Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kissei Pharmaceutical Co ( (JP:4547) ) just unveiled an update.
Kissei Pharmaceutical Co reported a significant financial performance for Fiscal 2024, with net sales reaching ¥88,330 million, marking a 16.9% increase year-over-year, and an operating profit of ¥5,773 million, a 43.7% rise. The growth was driven by increased sales in both domestic and international markets, particularly through the expansion of products like Linzagolix and Fostamatinib. The company also saw a rise in R&D expenses due to new product developments and licensing agreements, indicating a strategic focus on innovation and market expansion.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co is a company operating in the pharmaceutical industry, focusing on developing and marketing pharmaceuticals. The company is involved in both domestic and international markets, with a particular emphasis on expanding its presence through licensing agreements and marketing authorizations.
Average Trading Volume: 72,814
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen160.2B
For detailed information about 4547 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue